Vor Biopharma Inc. Stock Price, News & Analysis

Vor Bio (Nasdaq: VOR) announced publication in The New England Journal of Medicine of a China Phase 3 trial of telitacicept in systemic lupus erythematosus (SLE).

The randomized 335-patient study across 42 hospitals met its primary endpoint at week 52: 67.1% response for telitacicept versus 32.7% for placebo (P<0.001). Key secondary results: SELENA-SLEDAI ≥4 point reduction in 70.1% vs 40.5%; mean SELENA-SLEDAI change -4.95 vs -1.0; median time to flare 198 vs 115 days; steroid reduction in 44.9% vs 34.7%; kidney proteinuria improvements 71.8% vs 55.1%. Safety: more URTI (31.7% vs 19.0%) and injection-site reactions (12.6% vs 0.6%); serious adverse events were lower (7.2% vs 14.3%).

Vor Bio (NASDAQ: VOR) announced positive 48-week China Phase 3 results for telitacicept in primary Sjögren’s disease, presented at ACR Convergence 2025 on October 28, 2025. The 160mg dose met the primary endpoint (change in ESSDAI at week 24) and all secondary endpoints with p<0.0001 versus placebo, showing durable benefit through 48 weeks.

Key metrics: 71.8% of patients on 160mg achieved ≥3-point ESSDAI reduction at week 24 vs 19.3% placebo; mean ESSDAI change at week 24 was -4.4 (160mg) vs -0.6 (placebo). Safety was comparable to placebo with no new signals.

Vor Bio (Nasdaq: VOR) announced on Oct 3, 2025 that on Sept 19, 2025 its Compensation Committee granted inducement awards to eight newly hired employees under the 2023 Inducement Plan.

The grants consist of 76,360 stock options (10‑year term) and 16,361 RSUs. The option exercise price is $30.40 per share (closing price on grant date). Options vest over four years (25% after 12 months, then monthly over 36 months); RSUs vest over four years (25% after 12 months, then quarterly over 36 months). Awards are subject to plan and award agreement terms and continued employment.

Vor Bio (NASDAQ:VOR) announced that clinical data from their Phase 3 study of telitacicept in primary Sjögren's disease will be presented at ACR Convergence 2025 (October 24-29, 2025) in Chicago. The study, conducted in collaboration with RemeGen Co., Ltd, will be featured as a late-breaking poster presentation.

Notably, RemeGen has already submitted a Biologics License Application (BLA) to China's National Medical Products Administration for telitacicept in primary Sjögren's disease. If approved, this will mark telitacicept's fourth approved indication in China.

Vor Bio (Nasdaq: VOR) has appointed Dr. Navid Z. Khan as Chief Medical Affairs Officer. With over 20 years of experience, Dr. Khan brings extensive expertise in medical affairs, commercial operations, and R&D. He has overseen 40+ development programs and led seven successful product launches in rare neurology and immunology indications.

Most recently at argenx, Dr. Khan headed the Neuromuscular Therapeutic Area, Medical Affairs, where he led four launches of VYVGART® products. His previous roles include leadership positions at Akouos Inc. and Sarepta Therapeutics, where he was instrumental in launching three Duchenne muscular dystrophy therapies and preparing the company's Medical Affairs organization for gene therapy programs.

RemeGen (REGMY) announced that its 48-week open-label extension data from the China Phase III clinical study of telitacicept for generalized myasthenia gravis (gMG) has been selected for oral presentation at the 2025 AANEM Annual Meeting on October 29, 2025.

The previously presented 24-week data showed exceptional results with 98.1% of patients achieving ≥3 points improvement in MG-ADL score and 87% achieving ≥5 points improvement in QMG score, demonstrating the highest MG-ADL response rate among Phase III gMG treatments. In June 2025, RemeGen out-licensed telitacicept to Vor Bio (VOR), which is now conducting global Phase III trials across multiple regions.

Vor Bio (NASDAQ:VOR) announced that 48-week clinical data from their Phase 3 study of telitacicept in adults with generalized myasthenia gravis will be presented at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. The study, conducted in China and sponsored by Vor's collaborator RemeGen, will be featured as an oral presentation on October 29, 2025, at 10:50am PT at the Hilton San Francisco Union Square.

The presentation will focus on the efficacy and safety results of telitacicept in patients with generalized myasthenia gravis, as part of the Myasthenia Gravis Foundation of America session.

Vor Bio (NASDAQ:VOR), a clinical-stage biotech company focused on autoimmune disease treatments, has announced its participation in the upcoming Stifel 2025 Virtual Immunology and Inflammation Forum. The company will engage in a fireside chat on Monday, September 15, 2025, from 4:00-4:25 pm ET in Track 1.

The virtual event will also include one-on-one meetings with investors. Both live webcast and replay of the fireside chat will be accessible through Vor Bio's investor relations website.

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on autoimmune diseases, has appointed Dr. Adi Osovsky as General Counsel. Dr. Osovsky brings 17 years of experience in biotechnology and pharmaceutical legal counsel.

Dr. Osovsky joins from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. She previously held senior legal roles at Sarepta Therapeutics and was an associate at Sullivan & Worcester LLP. She holds an LL.B. from Tel Aviv University and both an LL.M. and S.J.D. in Securities Regulation from Harvard Law School.